Cerebral Antivasoconstrictive Effects of Flunarizine

References

• Hirschberg M. Calcium antagonists in an animal model of vertebrobasilar insufficiency. Symposium on Calcium and the Vestibular System, Beerse, April, 1988, 28–29
   Google Scholar
• Hofferberth B. Calcium antagonists in the treatment of vestibular insufficiency. Symposium on Calcium and the Vestibular System, Beerse, April, 28-291988
   Google Scholar
• Vanhoutte P. Possible pharmacological approaches to the treatment of peripheral vascular disease. Vascular Diseases, E Strandness, P Didisheim, A Clowes, J Watson. Grune & Stratton Inc., OrlandoUSA 1987; 151–82
   Google Scholar
• Vanhoutte P M, Paoletti R. The WHO classification of calcium antagonists. Trends Pharmacol Sci 1987; 8: 4–5
   Web of Science ®Google Scholar
• Vanhoutte P M. The expert committee of the World Health Organization on classification of calcium antagonists: the viewpoint of the raporteur. Am J Cardiol 1987; 59: 3A–8A
   Google Scholar
• Fleckenstein A. Calcium Antagonism in Heart and Smooth Muscle. Experimental Facts and Therapeutic Prospects. John Wiley & Sons, New York 1983
   Google Scholar
• Bolton T B. Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev 1979; 59: 606–718
   PubMed Web of Science ®Google Scholar
• Van Breemen C, Aaronson P, Loutzenhiser R. Sodium-calcium interactions in mammalian smooth muscle. Pharmacol Rev 1979; 30: 167–208
   Google Scholar
• Högestätt E D, Andersson K E. Mechanisms behind the biphasic contractile response to potassium depolarization in isolated rat cerebral arteries. J Pharmacol Exp Ther 1984; 228: 187–95
   PubMedGoogle Scholar
• Van Nueten J M, Janssen P AJ. Comparative study of the effects of flunarizine and cinnarizine on smooth muscles and cardiac tissues. Arch Int Pharmacodyn Ther 1973; 204: 37–55
   PubMedGoogle Scholar
• Godfraind T. Mechanisms of action of calcium entry blockers. Fed Proc 1981; 40: 2866–71
   PubMedGoogle Scholar
• Van Meel C A, Towart R, Kazda S, Timmermans P BMWM, van Zwieten P A. Correlation between the inhibitory activities of calcium entry blockers on vascular smooth muscle constriction in vitro after K+-depolarisation and in vivo after a2-adrenoceptor stimulation. Naunyn Schmiedebergs Arch Pharmacol 1983; 322: 34–7
   PubMedGoogle Scholar
• Godfraind T, Kaba A. The role of calcium in the action of drugs on vascular smooth muscle. Arch Int Pharmacodyn Ther 1972; 196: 35–49
   Google Scholar
• Van Nueten J M, Janssens W J, Vanhoutte P M. Calcium antagonism and vascular smooth muscle. Ann NY Acad Sci 1988; 522: 234–47
   PubMedGoogle Scholar
• Godfraind T. Classification of calcium antagonists. Symposium on Calcium and the Vestibular System, Beerse, April, 28-291988
   Google Scholar
• Van Nueten J M. Calcium entry blockers and vascular smooth muscle reactivity. Calcium Entry Blockers and Tissue Protection, T Godfraind, et al. Raven Press, New York 1985; 69–79
   Google Scholar
• Vanhoutte P M, Verbeuren T J, Webb R C. Local modulation of adrenergic neuroeffector interaction in the blood vessel wall. Physiol Rev 1981; 61: 151–247
   PubMed Web of Science ®Google Scholar
• De Clerck F, Van Nueten J M. Platelet-mediated vascular contractions. Inhibition by flunarizine, a calcium-entry blocker. Biochem Pharmacol 1983; 32: 765–71
   PubMed Web of Science ®Google Scholar
• Van Nueten J M, De Ridder W, Van Gorp L, De Clerck F. Vasoconstrictor expression of human platelet-vessel wall interactions: inhibition by the Ca24 entry blocker flunarizine. Eur J Pharmacol 1987; 133: 301–8
   PubMedGoogle Scholar
• De Clerck F, Van Nueten J M. Platelet-mediated vascular contractions: inhibition of the seroton-ergic component by ketanserin. Thromb Res 1982; 27: 713–27
   PubMedGoogle Scholar
• Van Nueten J M, Janssens W J, Vanhoutte P M. Serotonin and vascular reactivity. Pharmacol Res Commun 1985; 17: 585–608
   PubMedGoogle Scholar
• Van Nueten J M. Antivasoconstrictor effects of drugs used in migraine therapy. The Pharmacological Basis of Migraine Therapy, W K Amery, J M Van Nueten, A Wauquier. Pitman Publishing Ltd, LondonGreat Britain 1984; 19–35
   Google Scholar
• Van Nueten J M. Cerebrovascular reactivity to calcium and platelet-vessel wall interaction in pathology. Münchener Medizinische Wochenschrift 1988, (submitted)
   Google Scholar
• Katusic Z S, Vanhoutte P M. Anoxic contractions in isolated canine cerebral arteries: contribution of endothelium-derived factors, metabolites of arachidonic acid, and calcium entry. J Cardiovasc Pharmacol 1986; 8(Suppl 8)S97–S101
   Google Scholar
• Vanhoutte P M, Rubanyi G M, Miller V M, Houston D S. Modulation of vascular smooth muscle contraction by the endothelium. Ann Rev Physiol 1986; 48: 307–20
   PubMed Web of Science ®Google Scholar
• Hladovec J, De Clerck F. Protection by flunarizine against endothelial cell injury in vivo. Angiology 1981; 32: 448–62
   PubMedGoogle Scholar
• Vanhoutte P M. Endothelium and the control of vascular tissue. News Physiol Sci 1987; 2: 18–22
   Google Scholar
• De Mey J G, Vanhoutte P M. Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res 1982; 51: 439–47
   PubMed Web of Science ®Google Scholar
• De Mey J G, Vanhoutte P M. Anoxia and endothelium-dependent reactivity of the canine femoral artery. J Physiol 1983; 335: 65–74
   PubMed Web of Science ®Google Scholar
• Rubanyi G M, Vanhoutte P M. Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. J Physiol 1985; 364: 45–56
   PubMed Web of Science ®Google Scholar
• Van Nueten J M, Vanhoutte P M. Flunarizine. New Drugs Annual: Cardiovascular Drugs, A Scriabine. Raven Press, New York 1984; 245–66
   Google Scholar
• De Clerck F, Beerens M, Thoné F, Borgers M. Effect of flunarizine on the human red cell shape changes and calcium deposition induced by A23187. Thromb Res 1981; 24: 1–12
   PubMedGoogle Scholar
• Van Nueten J M, Van Beek J, Janssen P AJ. Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Arch Int Pharmacodyn Ther 1978; 232: 42–52
   PubMedGoogle Scholar
• Van Nueten J M, Van Beek J, Janssen P AJ. The vascular effects of flunarizine as compared with those of other clinically used vasoactive substances. Arzneimittelforschung/Drug Res 1978; 28: 2082–7
   PubMedGoogle Scholar
• Van Nueten J M. Selectivity of calcium entry blockers. Calcium Modulators, T Godfraind, A Albertini, R Paoletti. Elsevier Biomedical Press, RotterdamNederland 1982; 199–208
   Google Scholar
• Jonkman F AM, Boddeke H WGM, van Zwieten P A. Protective activity of calcium entry blockers against ouabain intoxication in anesthetized guinea pigs. J Cardiovasc Pharmacol 1986; 8: 1009–13
   PubMedGoogle Scholar
• De Clerck F, Loots W, Voeten J, Janssen P AJ. Differential effects of verapamil and flunarizine on epinephrine-induced vasoconstriction and on spontaneous vasomotion of arterioles in skeletal muscle in the rat in vivo. J Cardiovasc Pharmacol 1988
   Google Scholar
• Favalli L, Lanza E, Rozza Dionigi A, Assogna G, Goggi D, Ricevuti G. Flunarizine, cerebral blood flow and reversion of experimental atherosclerosis in rabbit. Drugs Exptl Clin 1985; XI: 845–50
   Google Scholar
• Di Perri T, Laghi Pasini F, Guerrini M, Cappelli R, Pecchi S. (1984) Treatment of peripheral obliterative arterial disease with calcium-entry blocker drugs. Proceedings of the Fifth International Meeting on Atherosclerosis, BolognaItaly, November, 28-301983, S Lenzi, G Descovich. MTP Press Limited, CLancaster Boston, The Hague, Dordrecht, 14–126, Atherosclerosis and cardiovascular disease. Aetiopathogenesis, epidemiology, clinical evaluation, prevention and therapy.
   Google Scholar